3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lymphoma, B-Cell
2
Liver Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Bevacizumab
11
atezolizumab
8
Specimen Handling
7
Magnetic Resonance Spectroscopy
7
Nivolumab
6
durvalumab
5
tremelimumab
3
lenvatinib
3
cabozantinib
3
Ipilimumab
3
ulixertinib
2
tislelizumab
2
relatlimab
2
donafenib
2
camrelizumab
2
apatinib
2
X-Rays
2
Surgical Procedures, Operative
2
Sorafenib
2
Oxaliplatin
2
Leucovorin
2
Immunotherapy
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
trametinib
1
sonidegib
1
sofosbuvir-velpatasvir drug combination
1
sintilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Cell- and Tissue-Based Therapy
×
30 days
×
Clear all
NCT06084884
2026-05-22
ATHENA
AstraZeneca
Phase 1/2
Active not recruiting
94 enrolled